Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $41.24M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: 4121.12%
• EPS Growth: 83.30%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 87,307,090
• 10 Day Avg. Volume: 1,954,645
• 30 Day Avg. Volume: 1,333,579
• PEG Ratio: 0.02
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 12.06
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: -1.08
• Enterprise Value/Revenue: -0.39
• Enterprise Value/Gross Profit: -0.42
• Enterprise Value/Ebitda: 3.15
• 1Y Price Target: $4.50
• Price Target Upside: 733.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▼(-7.41% Downside)

Century Therapeutics' overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but ongoing operational losses. The technical analysis indicates a bearish trend, and the valuation reflects the company's current unprofitability. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates successful commercialization efforts and increasing market acceptance of its innovative therapies, supporting long-term business expansion.

Strong Balance Sheet

A strong equity ratio suggests financial stability and lower risk, providing the company with flexibility to invest in R&D and withstand market fluctuations.

Proprietary Technology

The proprietary iPSC technology offers a competitive edge by enabling scalable and customizable cancer treatments, potentially leading to sustained market leadership.

Negative Factors

Operating Losses

Ongoing net losses highlight operational inefficiencies and the challenge of managing high fixed costs, which could hinder profitability and require strategic adjustments.

Negative Cash Flow

Negative cash flow indicates cash burn and reliance on external funding, which may limit the company's ability to invest in growth initiatives and sustain operations long-term.

High Fixed Costs

High fixed costs can pressure margins and profitability, necessitating strategic cost management to improve operational efficiency and financial performance.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics is a biotechnology company focused on developing and commercializing innovative cell therapies for the treatment of cancer. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, Century aims to create off-the-shelf, genetically engineered immune cell therapies that can be tailored for multiple cancer types. The company operates within the sectors of regenerative medicine and oncology, with core products centered around its iPSC-derived cell therapies designed to enhance the efficacy and accessibility of cancer treatments.

How the Company Makes Money

Century Therapeutics generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of developed therapies. Additionally, the company may receive funding from grants and investments to support its research and development efforts. By focusing on advancing its proprietary iPSC technology, Century aims to establish a strong pipeline of therapies that can be licensed or commercialized, contributing to its overall revenue growth.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics shows significant revenue growth but continues to operate at a net loss with negative EBIT and EBITDA margins. The balance sheet is strong with a high equity ratio and healthy cash reserves, but cash flow is negative, indicating operational inefficiencies.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	113.34M	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	107.01M	6.59M	2.23M	5.20M	-4.58M	-1.75M
EBITDA	-14.21M	-111.47M	-121.21M	-121.20M	-89.92M	-51.44M
Net Income	-26.48M	-126.57M	-136.67M	-130.93M	-95.82M	-53.58M
Balance Sheet
Total Assets	244.72M	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	132.75M	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	44.96M	53.83M	48.17M	49.41M	25.12M	21.55M
Total Liabilities	68.37M	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	176.35M	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-112.69M	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-112.02M	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	115.75M	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	-482.00K	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.54
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 0.54 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.54, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.03 is Neutral, neither overbought nor oversold. The STOCH value of 79.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	45 Neutral	$42.50M	―	-104.58%	―	―	1.18%
ATNM	41 Neutral	$42.11M	-1.03	-133.09%	―	11.11%	20.65%
IPSC	41 Neutral	$41.24M	―	-14.23%	―	4121.12%	83.30%
TPST	39 Underperform	$40.49M	-0.62	-405.03%	―	―	49.43%
CALC	39 Underperform	$56.92M	―	-526.36%	―	―	-2.46%
BTAI	37 Underperform	$36.54M	-0.15	―	―	-66.96%	71.83%

Century Therapeutics Corporate Events

Century Therapeutics Reports Positive Q3 2025 Earnings

Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic cell therapies for treating solid tumors, hematological malignancies, and autoimmune diseases. In its latest earnings report for the quarter ending September 30, 2025, Century Therapeutics revealed a net income of $9.6 million, a significant improvement from a net loss of $90.5 million in the same period last year. This turnaround was largely driven by $109.2 million in collaboration revenue recognized in the first quarter following the termination of a collaboration agreement with Bristol-Myers Squibb. The company’s cash and cash equivalents stood at $55.5 million, with total assets amounting to $244.7 million, down from $353.2 million at the end of 2024, reflecting a decrease in short-term investments and operating lease assets. Despite the positive net income, Century Therapeutics continues to face challenges, including a decrease in cash flow from operations and a reduction in total assets. The company remains focused on its strategic partnerships and the development of its innovative cell therapy products. Looking ahead, Century Therapeutics aims to continue advancing its product candidates through clinical trials and is committed to addressing unmet medical needs in oncology and autoimmune diseases.

Century Therapeutics Launches Type 1 Diabetes Program

On November 13, 2025, Century Therapeutics announced the launch of its first program for Type 1 diabetes, CNTY-813, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND in 2026. The company is also advancing CNTY-308 through IND-enabling studies for B-cell-mediated diseases, targeting clinical study initiation in 2026. Additionally, Century reported a net loss of $34.4 million for the third quarter of 2025, with a cash runway estimated to extend into the fourth quarter of 2027, reflecting a strategic focus on high-impact therapeutic areas and resource allocation.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors

Study Overview: Century Therapeutics, Inc. is conducting a long-term follow-up study titled A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product. The study aims to gather safety and survival data from participants previously treated with Century’s cellular therapy products. It focuses on identifying late adverse events and assessing long-term risks associated with these treatments, which are crucial for understanding the safety profile of these innovative therapies.

Century Therapeutics’ CALiPSO-1 Study: A Promising Step in Autoimmune Disease Treatment

Century Therapeutics, Inc. is conducting the CALiPSO-1 study, officially titled A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases. This Phase 1 study aims to assess the safety and efficacy of CNTY-101 in treating refractory B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and diffuse cutaneous systemic sclerosis.

Century Therapeutics Granted Nasdaq Compliance Extension

On February 26, 2025, Century Therapeutics received a deficiency letter from Nasdaq due to non-compliance with the $1.00 minimum bid price requirement. Despite failing to meet the initial compliance deadline of August 26, 2025, Nasdaq granted an extension until February 23, 2026, and approved the company’s transfer to The Nasdaq Capital Market. Century Therapeutics plans to monitor its stock price and consider a reverse stock split to regain compliance, although there is no assurance of success.

The most recent analyst rating on (IPSC) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Reports Q2 2025 Financials and Updates

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer. The company leverages its expertise in cellular reprogramming and genetic engineering to create off-the-shelf cell therapies aimed at improving patient access and treatment outcomes.

Century Therapeutics Reports Q2 Results and Leadership Change

On August 14, 2025, Century Therapeutics announced its second quarter financial results and business updates, highlighting ongoing patient dosing in the CALiPSO-1 trial and progress in IND-enabling studies for CNTY-308. The company extended its cash runway into the fourth quarter of 2027 following a workforce reduction and strategic focus on high-potential programs. CEO Brent Pfeiffenberger was appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor. The company remains on track to report clinical data for CNTY-101 by the end of 2025 and plans to initiate clinical studies for CNTY-308 in 2026.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.